EMA Grants PRIME Designation to Oculis' Privosegtor, Accelerating First-in-Class Optic Neuritis Treatment
summarizeSummary
Oculis' Privosegtor has received European Medicines Agency (EMA) PRIME designation for optic neuritis, a significant regulatory milestone that provides accelerated development and review support for promising medicines. This follows a similar Breakthrough Therapy designation from the U.S. FDA in January 2026, underscoring strong global regulatory confidence in the potential first-in-class neuroprotective candidate. The designation is supported by compelling Phase 2 ACUITY trial results and aims to expedite market access for a drug targeting a substantial unmet medical need. This dual regulatory support significantly de-risks the development pathway and highlights the drug's commercial potential as Oculis advances its PIONEER registrational program, with the first trial initiated in Q4 2025.
At the time of this announcement, OCS was trading at $24.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $14.00 to $30.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.